Forecasting Readmission Risk in Older Heart Failure Patients with Frailty Assessment Tools

Authors

  • Dong-Hyun Lee Department of Anesthesiology and Pain Medicine, College of Medicine, Chonnam National University, Gwangju, Republic of Korea Author

Keywords:

Heart Failure, Frailty Assessment, Hospital Readmission, Cohort Studies, Readmission Risk

Abstract

The intersection of advanced age and chronic heart failure presents a profound challenge to modern healthcare systems, primarily driven by high rates of hospital readmission. Traditional risk stratification models often fail to account for the complex vulnerability associated with biological aging, specifically the syndrome of frailty. This paper presents a comprehensive cohort study designed to evaluate and predict readmission risk in older heart failure patients utilizing multiple validated frailty assessment tools. By integrating clinical, demographic, and geriatric assessment data from a prospective cohort, the study systematically compares the predictive utility of instruments such as the Fried Phenotype and the Clinical Frailty Scale. The primary objective is to determine how the incorporation of frailty metrics into standard clinical models enhances the precision of predicting thirty-day and ninety-day readmissions. Furthermore, the analysis explores the underlying trajectories of functional decline that precipitate acute decompensation. The findings aim to facilitate a transition from disease-centric risk assessment to a multidimensional, patient-centered paradigm, ultimately guiding targeted interventions to mitigate the escalating cycle of recurrent hospitalizations in this vulnerable demographic.

References

1. Mostafa, S.; Rafizadeh, R.; Polasek, T.M.; Bousman, C.A.; Rostami-Hodjegan, A.; Stowe, R.; Carrion, P.; Sheffield, L.J.; Kirkpatrick, C.M.J. Virtual twins for model-informed precision dosing of clozapine in patients with treatment-resistant schizophrenia. CPT Pharmacomet. Syst. Pharmacol. 2024, 13, 424–436.

2. El Hassani, M.; Marsot, A. External Evaluation of Population Pharmacokinetic Models for Precision Dosing: Current State and Knowledge Gaps. Clin. Pharmacokinet. 2023, 62, 533–540.

3. Zhou, X.; Dun, J.; Chen, X.; Xiang, B.; Dang, Y.; Cao, D. Predicting the Correct Dose in Children: Role of Computational PBPK Modeling Tools. CPT Pharmacomet. Syst. Pharmacol. 2022, 12, 13–26.

4. Pan, Y.; He, X.; Yao, X.; Yang, X.; Wang, F.; Ding, X.; Wang, W. The effect of body mass index and creatinine clearance on serum trough concentration of vancomycin in adult patients. BMC Infect. Dis. 2020, 20, 341.

5. Dzobo, K.; Khumalo, N.; Mora, V.Z.; Zoncsich, A.; De Mezerville, R.; Bayat, A. Advances in Silicone Implants Characterization: A Comprehensive Overview of Chemical, Physical and Biological Methods for Biocompatibility Assessment. Bioengineering 2025, 12, 1307.

6. Fendt, R.; Hofmann, U.; Schneider, A.R.P.; Schaeffeler, E.; Burghaus, R.; Yilmaz, A.; Blank, L.M.; Kerb, R.; Lippert, J.; Schlender, J.F.; et al. Data-driven personalization of a physiologically based pharmacokinetic model for caffeine: A systematic assessment. CPT Pharmacomet. Syst. Pharmacol. 2021, 10, 782–793.

7. Polasek, T.M.; Tucker, G.T.; Sorich, M.J.; Wiese, M.D.; Mohan, T.; Rostami-Hodjegan, A.; Korprasertthaworn, P.; Perera, V.; Rowland, A. Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation. Br. J. Clin. Pharmacol. 2018, 84, 462–476.

8. Tsantili-Kakoulidou, A.; Demopoulos, V.J. Drug-like Properties and Fraction Lipophilicity Index as a combined metric. ADMET DMPK 2021, 9, 177–190.

9. Rostami-Hodjegan, A.; Al-Majdoub, Z.M.; von Grabowiecki, Y.; Yee, K.L.; Sahoo, S.; Breitwieser, W.; Galetin, A.; Gibson, C.; Achour, B. Dealing With Variable Drug Exposure Due to Variable Hepatic Metabolism: A Proof-of-Concept Application of Liquid Biopsy in Renal Impairment. Clin. Pharmacol. Ther. 2024, 116, 814–823.

10. Berry, D.A. Interim Analysis in Clinical Trials: The Role of the Likelihood Principle. Am. Stat. 1987, 41, 117–122.

11. Maharaj, A.R.; Wu, H.; Hornik, C.P.; Arrieta, A.; James, L.; Bhatt-Mehta, V.; Bradley, J.; Muller, W.J.; Al-Uzri, A.; Downes, K.J.; et al. Use of normalized prediction distribution errors for assessing population physiologically-based pharmacokinetic model adequacy. J. Pharmacokinet. Pharmacodyn. 2020, 47, 199–218.

12. Ivanescu, A.E.; Li, P.; George, B.; Brown, A.W.; Keith, S.W.; Raju, D.; Allison, D.B. The importance of prediction model validation and assessment in obesity and nutrition research. Int. J. Obes. 2016, 40, 887–894.

13. Chou, P.; Shannar, A.; Pan, Y.; Dave, P.D.; Xu, J.; Kong, A.-N.T. Application of Physiologically-Based Pharmacokinetic (PBPK) Model in Drug Development and in Dietary Phytochemicals. Curr. Pharmacol. Rep. 2025, 11, 45.

14. Diamond, G.A.; Kaul, S.J. Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials. Am. Coll. Cardiol. 2004, 43, 1929–1939.

Downloads

Published

2026-03-22

Issue

Section

Articles